Our AI instantly delivers powerful, actionable diabetes insights from one of the world’s richest diabetes datasets.
Our survey of Canada’s type 1 diabetes community reveals COVID-19’s impact on medication access, diet, exercise, hyperglycemia, and overall well-being.
Our April 2020 dQ&A survey of 4,700 U.S. diabetes patients finds supply chains largely intact yet short-term delays and risky pharmacy visits hinder refills.
Our second COVID-19 impact survey of 4,500+ U.S. diabetes patients found ongoing drug/supply delays, care disruptions, and declines in diet and exercise.
Our study of US patients explores insulin rationing’s physical & emotional impact through qualitative & quantitative research. Check out the community video.
This survey explores the impact of COVID-19 on diabetes management, revealing high concern, precautionary steps, and changes in work and daily routines.
Part 1 of dQ&A’s CGM Series charts the rapid global rise of continuous glucose monitoring (CGM) —why uptake is soaring, benefits for patients, and what’s next.
Our 10-year member journeys reveal a powerful window into the diabetes patient experience, showing advances and the challenges that still remain.
A recent patient-reported outcome (PRO) measurement found that reduced hypoglycemia awareness is common in both type 1 and type 2 diabetes.
